Artelo Biosciences (ARTL) Free Cash Flow (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Free Cash Flow of -$2.9 million for Q4 2025, down 13.4% year-over-year from -$3.4 million in Q4 2024, and up 16.78% quarter-over-quarter from -$3.5 million in Q3 2025.
Artelo Biosciences (ARTL) Free Cash Flow (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Free Cash Flow for 12 consecutive years, with -$2.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow fell 13.4% year-over-year to -$2.9 million; the TTM figure through Dec 2025 stood at -$8.5 million (down 2.04% YoY), while the FY2025 annual figure was -$8.3 million, changed 0.22% from the prior year.
- Free Cash Flow climbed to -$2.9 million in Q4 2025 per ARTL's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$514000.0 in Q2 2025 and bottomed at -$3.5 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$2.0 million across 5 years, with a median of -$2.0 million in 2022.
- On a YoY basis, Free Cash Flow climbed as much as 75.08% in 2025 and fell as far as 349.61% in 2025.
- Artelo Biosciences' Free Cash Flow stood at -$1.9 million in 2021, then declined by 19.06% to -$2.3 million in 2022, then declined by 13.21% to -$2.6 million in 2023, then gained by 1.12% to -$2.6 million in 2024, then dropped by 13.4% to -$2.9 million in 2025.
- Business Quant data shows ARTL's Free Cash Flow at -$2.9 million in Q4 2025, -$3.5 million in Q3 2025, and -$514000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | -2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.91 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -514,000.00 |
| Jun 30, 2025 | -514,000.00 |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Sep 30, 2024 | -778,000.00 |
| Sep 30, 2024 | -778,000.00 |
| Jun 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -2.06 Mn |
| Mar 31, 2024 | -2.94 Mn |
| Mar 31, 2024 | -2.94 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |